139 related articles for article (PubMed ID: 28164611)
1. Serum Level of Matrix Metalloproteinase-9 in Patients with Head and Neck Squamous Cell Carcinoma.
Stanciu AE; Zamfir-Chiru-Anton A; Stanciu MM; Popescu CR; Gheorghe DC
Clin Lab; 2016 Aug; 62(8):1569-1574. PubMed ID: 28164611
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
3. Imbalance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Promotes Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma.
Stanciu AE; Zamfir-Chiru-Anton A; Stanciu MM; Popescu CR; Gheorghe DC
Clin Lab; 2017 Oct; 63(10):1613-1620. PubMed ID: 29035450
[TBL] [Abstract][Full Text] [Related]
4. Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract.
Wang WL; Chang WL; Yeh YC; Lee CT; Chang CY; Lin JT; Sheu BS
Mol Carcinog; 2013 Jun; 52(6):438-45. PubMed ID: 22241750
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck].
Al Kassam D; Alvarez Marcos C; Blanco I; de Los Toyos JR; Llorente JL
Med Clin (Barc); 2007 Dec; 129(20):761-5. PubMed ID: 18093475
[TBL] [Abstract][Full Text] [Related]
6. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Int J Cancer; 2005 Sep; 116(3):422-7. PubMed ID: 15818624
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Clin Cancer Res; 2004 May; 10(9):3110-6. PubMed ID: 15131051
[TBL] [Abstract][Full Text] [Related]
8. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
[TBL] [Abstract][Full Text] [Related]
11. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract][Full Text] [Related]
12. Analysis of preoperative serum levels of MMP1, -2, and -9 in patients with site-specific head and neck squamous cell cancer.
Kalfert D; Ludvikova M; Topolcan O; Windrichova J; Malirova E; Pesta M; Celakovsky P
Anticancer Res; 2014 Dec; 34(12):7431-41. PubMed ID: 25503184
[TBL] [Abstract][Full Text] [Related]
13. Determination of matrix metalloproteinase 9 (MMP-9) protein expression in laryngeal squamous cell carcinomas based on digital image analysis.
Papadas TA; Naxakis SS; Mastronikolis NS; Stathas T; Karabekos NCh; Tsiambas E
J BUON; 2013; 18(4):977-81. PubMed ID: 24344026
[TBL] [Abstract][Full Text] [Related]
14. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma.
Mannello F
Cancer; 2003 Jan; 97(1):201-3; author reply 203-4. PubMed ID: 12491521
[No Abstract] [Full Text] [Related]
15. Prognostic molecular markers in head and neck squamous cell carcinoma in a New Zealand population: matrix metalloproteinase-2 and sialyl Lewis x antigen.
Gunawardena I; Arendse M; Jameson MB; Plank LD; Gregor RT
ANZ J Surg; 2015 Nov; 85(11):843-8. PubMed ID: 24171785
[TBL] [Abstract][Full Text] [Related]
16. Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma.
Wiegand S; Dünne AA; Müller HH; Mandic R; Barth P; Davis RK; Werner JA
Cancer; 2005 Jul; 104(1):94-100. PubMed ID: 15912516
[TBL] [Abstract][Full Text] [Related]
17. Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis.
Kawata R; Shimada T; Maruyama S; Hisa Y; Takenaka H; Murakami Y
Acta Otolaryngol; 2002 Jan; 122(1):101-6. PubMed ID: 11876588
[TBL] [Abstract][Full Text] [Related]
18. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma.
Ranuncolo SM; Matos E; Loria D; Vilensky M; Rojo R; Bal de Kier Joffé E; Inés Puricelli L
Cancer; 2002 Mar; 94(5):1483-91. PubMed ID: 11920505
[TBL] [Abstract][Full Text] [Related]
19. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
[TBL] [Abstract][Full Text] [Related]
20. NFκB-p50 as a blood based protein marker for early diagnosis and prognosis of head and neck squamous cell carcinoma.
Gupta A; Kumar R; Sahu V; Agnihotri V; Singh AP; Bhasker S; Dey S
Biochem Biophys Res Commun; 2015 Nov; 467(2):248-53. PubMed ID: 26435503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
